{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:51:25Z","timestamp":1793361085767,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Light chain\u2013associated amyloidosis (AL) is a plasma cell dyscrasia in which the secreted monoclonal immunoglobulin (Ig) light chains form amyloid fibrils. There is considerable heterogeneity in clinical presentation, and prognosis of the disease relates to the severity of organ dysfunction induced by amyloid deposits. The mechanisms by which the amyloid fibrils are deposited as well as the predilection for specific organ sites have not been clearly elucidated. This study characterizes the repertoire of immunoglobulin light chain variable genes used by the clonal B cell in AL amyloid patients, and the association of light chain variable region (VL) genes with clinical presentation and outcome is assessed in 58 (32 \u03bb and 26 \u03ba) patients. A preferential use of VL germ-line genes was noted for both AL \u03ba and \u03bb patients. There was a significant correlation between the use of the V\u03bb VI germ-line donor, 6a, and renal involvement as well as the V\u03bb III gene, 3r, with soft-tissue AL. The use of a biased VL gene repertoire also correlated with clinical outcome, revealing important trends for predicting prognosis. The use of V\u03bb II germ-line genes was associated with cardiac amyloidosis and affected survival adversely. The presence of multiple myeloma also correlated with a poor prognosis. The presence of renal disease, on the other hand, was associated with improved survival. Therefore, identification of the clonal VL gene in AL has important implications in determining clinical outcome.<\/jats:p>","DOI":"10.1182\/blood-2002-09-2707","type":"journal-article","created":{"date-parts":[[2003,5,5]],"date-time":"2003-05-05T19:24:00Z","timestamp":1052162640000},"page":"3801-3807","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":200,"title":["Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain\u2013associated amyloidosis (AL)"],"prefix":"10.1182","volume":"101","author":[{"given":"Roshini S.","family":"Abraham","sequence":"first","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy L.","family":"Price-Troska","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Biochemistry and Immunology, the Division of Hematology, and the Division of Biostatistics, Mayo Cancer Center, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702103641900_B1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0889-8588(05)70122-2","article-title":"Amyloidosis.","volume":"13","author":"Gertz","year":"1999","journal-title":"Hematol Oncol Clin North Am."},{"key":"2019111702103641900_B2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0002-9149(85)90268-1","article-title":"Echocardiographic features of amyloid ischemic heart disease.","volume":"55","author":"Cueto-Garcia","year":"1985","journal-title":"Am J Cardiol."},{"key":"2019111702103641900_B3","first-page":"665","article-title":"Amyloidosis (AL): clinical and laboratory features in 229 cases.","volume":"58","author":"Kyle","year":"1983","journal-title":"Mayo Clin Proc."},{"key":"2019111702103641900_B4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0025-6196(12)65706-1","article-title":"Primary systemic amyloidosis\u2014a diagnostic primer.","volume":"64","author":"Gertz","year":"1989","journal-title":"Mayo Clin Proc."},{"key":"2019111702103641900_B5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","article-title":"Long-term survival (10 years or more) in 30 patients with primary amyloidosis.","volume":"93","author":"Kyle","year":"1999","journal-title":"Blood."},{"key":"2019111702103641900_B6","first-page":"313","article-title":"Prognostic value of urinary protein in primary systemic amyloidosis (AL).","volume":"94","author":"Gertz","year":"1990","journal-title":"Am J Clin Pathol."},{"key":"2019111702103641900_B7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood."},{"key":"2019111702103641900_B8","first-page":"218","article-title":"The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients.","volume":"84","author":"Perfetti","year":"1999","journal-title":"Haematologica."},{"key":"2019111702103641900_B9","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases.","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol."},{"key":"2019111702103641900_B10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood."},{"key":"2019111702103641900_B11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1365-2141.1999.01591.x","article-title":"Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation.","volume":"106","author":"Comenzo","year":"1999","journal-title":"Br J Haematol."},{"key":"2019111702103641900_B12","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","article-title":"Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.","volume":"100","author":"Perfetti","year":"2002","journal-title":"Blood."},{"key":"2019111702103641900_B13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1309\/TWBM-8L4E-VK22-FRH5","article-title":"Chemical typing of amyloid protein contained in formalin-fixed paraffin- embedded biopsy specimens.","volume":"116","author":"Murphy","year":"2001","journal-title":"Am J Clin Pathol."},{"key":"2019111702103641900_B14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med."},{"key":"2019111702103641900_B15","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood."},{"key":"2019111702103641900_B16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med."},{"key":"2019111702103641900_B17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0025-6196(12)62409-4","article-title":"Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart.","volume":"59","author":"Cueto-Garcia","year":"1984","journal-title":"Mayo Clin Proc."},{"key":"2019111702103641900_B18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1046\/j.1537-2995.1998.38198141500.x","article-title":"Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application.","volume":"38","author":"Comenzo","year":"1998","journal-title":"Transfusion."},{"key":"2019111702103641900_B19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-1759(94)00286-6","article-title":"Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes.","volume":"179","author":"Welschof","year":"1995","journal-title":"J Immunol Methods."},{"key":"2019111702103641900_B20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/clinchem\/48.10.1805","article-title":"Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma.","volume":"48","author":"Abraham","year":"2002","journal-title":"Clin Chem."},{"key":"2019111702103641900_B21","first-page":"866","article-title":"Idiopathic AL-kiv amyloidosis presenting as giant hepatomegaly.","volume":"18","author":"Pras","year":"1982","journal-title":"Isr J Med Sci."},{"key":"2019111702103641900_B22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.510250122","article-title":"Hepatic amyloidosis: clinical appraisal in 77 patients.","volume":"25","author":"Gertz","year":"1997","journal-title":"Hepatology."},{"key":"2019111702103641900_B23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0002-9343(88)90505-0","article-title":"Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients.","volume":"85","author":"Gertz","year":"1988","journal-title":"Am J Med."},{"key":"2019111702103641900_B24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1749-6632.1995.tb55809.x","article-title":"Expression and hypermutation of human immunoglobulin kappa genes.","volume":"764","author":"Klein","year":"1995","journal-title":"Ann N Y Acad Sci."},{"key":"2019111702103641900_B25","first-page":"1139","article-title":"Variable kappa gene rearrangement in lymphoproliferative disorders: an analysis of V kappa gene usage, VJ joining and somatic mutation.","volume":"8","author":"Cannell","year":"1994","journal-title":"Leukemia."},{"key":"2019111702103641900_B26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/jmbi.1997.0956","article-title":"The creation of diversity in the human immunoglobulin V(lambda) repertoire.","volume":"268","author":"Ignatovich","year":"1997","journal-title":"J Mol Biol."},{"key":"2019111702103641900_B27","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.4049\/jimmunol.162.4.2137","article-title":"Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire.","volume":"162","author":"Farner","year":"1999","journal-title":"J Immunol."},{"key":"2019111702103641900_B28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0065-3233(08)60322-8","article-title":"Domain stability in immunoglobulin light chain deposition disorders.","volume":"50","author":"Wetzel","year":"1997","journal-title":"Adv Protein Chem."},{"key":"2019111702103641900_B29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI110635","article-title":"Bence Jones proteins and light chains of immunoglobulins: preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).","volume":"70","author":"Solomon","year":"1982","journal-title":"J Clin Invest."},{"key":"2019111702103641900_B30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/clin.1994.1070","article-title":"Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia.","volume":"71","author":"Ozaki","year":"1994","journal-title":"Clin Immunol Immunopathol."},{"key":"2019111702103641900_B31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pro.5560040309","article-title":"Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins.","volume":"4","author":"Stevens","year":"1995","journal-title":"Protein Sci."},{"key":"2019111702103641900_B32","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1182\/blood.V91.8.2948.2948_2948_2954","article-title":"Evidence that amyloidogenic light chains undergo antigen-driven selection.","volume":"91","author":"Perfetti","year":"1998","journal-title":"Blood."},{"key":"2019111702103641900_B33","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1172\/JCI115252","article-title":"Structure of a monoclonal kappa chain of the VKIV subgroup in the kidney and plasma cells in light chain deposition disease.","volume":"87","author":"Cogne","year":"1991","journal-title":"J Clin Invest."},{"key":"2019111702103641900_B34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2249.1992.tb06424.x","article-title":"Primary structure of a monoclonal kappa chain in myeloma with light chain deposition disease.","volume":"87","author":"Khamlichi","year":"1992","journal-title":"Clin Exp Immunol."},{"key":"2019111702103641900_B35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1097-2765(00)80429-3","article-title":"E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells.","volume":"5","author":"Romanow","year":"2000","journal-title":"Mol Cell."},{"key":"2019111702103641900_B36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1084\/jem.194.5.645","article-title":"Localized gene-specific induction of accessibility to V(D)J recombination induced by E2A and early B cell factor in nonlymphoid cells.","volume":"194","author":"Goebel","year":"2001","journal-title":"J Exp Med."},{"key":"2019111702103641900_B37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/blood.V75.3.531.531","article-title":"Amyloidosis: a final common pathway for protein deposition in tissues.","volume":"75","author":"Stone","year":"1990","journal-title":"Blood."},{"key":"2019111702103641900_B38","first-page":"200","article-title":"AL amyloidosis.","volume-title":"Amyloid and Amyloidosis.","author":"Solomon","year":"1994"},{"key":"2019111702103641900_B39","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/bi00242a001","article-title":"Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology.","volume":"30","author":"Stevens","year":"1991","journal-title":"Biochemistry."},{"key":"2019111702103641900_B40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF02816101","article-title":"Proteoglycans and other basement membrane proteins in amyloidoses.","volume":"9","author":"Kisilevsky","year":"1994","journal-title":"Mol Neurobiol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/10\/3801\/1261582\/h81003003801a.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/10\/3801\/1261582\/h81003003801a.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T16:51:58Z","timestamp":1682441518000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/10\/3801\/19403\/Immunoglobulin-light-chain-variable-V-region-genes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,15]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-09-2707","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,15]]}}}